Hubei Kelaiwei Biopharmaceutical Co., Ltd. announced that it has received an equity round of funding on July 31, 2020. The transaction included participation from Shaanxi Kanghui Pharmaceutical Co., Ltd. (SHSE:603139). The company completed the registration change at Industrial and Commercial Administration Authorities.